Skip to main content

Table 1 Baseline patient characteristics (safety analysis set)

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Characteristics n mean ± SD/%
Age (years) 659 60.8 ± 13.1
Men (%) 384 58.3
With complications (%) 551 83.6
Concurrent disease   
 Hypertension (%) 368 55.8
 Diabetes (%) 230 34.9
 Hepatic disease (%) 152 23.1
 Cardiac disease (%) 46 7.0
 Renal disease (%) 20 3.0
Purpose of combination therapy a   
 Primary prevention (%) 604 91.7
 Secondary prevention (%) 26 3.9
 Unknown (%) 29 4.4
Concomitant medications   
 Drugs for hypertension (%) 355 53.9
 Drugs for diabetes (%) 163 24.7
 Statin (%) 14 2.1
  1. Data are expressed as mean ± standard deviation or n and percent.
  2. aDefined according to the Guidelines for the Prevention of Atherosclerotic Cardiovascular Disease 2007 [9].